Diamond Entertainment

Diamond Therapeutics is a clinical-stage biotechnology company focused on developing low-dose, sub-perceptual psychedelic-derived medicines to treat mental health disorders. The company's primary focus is on utilizing psilocybin and other psychedelic compounds at dosages that do not produce hallucinogenic effects, aiming to provide therapeutic benefits without the need for intensive clinical supervision. Their lead program is currently being evaluated for indications such as major depressive disorder and various anxiety disorders. By prioritizing a non-hallucinogenic approach, Diamond Therapeutics seeks to expand patient access to psychedelic medicine through traditional pharmacy channels.